$Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development$

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Saved in:

Bibliographic Details
Main Authors:	Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial
Format:	Article
Language:	English
Published:	Nature Publishing Group 2025-03-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-025-01243-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
by: Pralay Mukhopadhyay, et al.
Published: (2025-02-01)

The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
by: Almodovar Diaz AA, et al.
Published: (2024-12-01)

Belantamab Mafodotin Monotherapy for Multiply‐Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland
by: Edmund C. R. Watson, et al.
Published: (2025-06-01)

Corneal Findings in Patients Treated with Belantamab Mafodotin: A Prospective Case Series Focusing on Corneal Nerves
by: Jakob Schweighofer, et al.
Published: (2025-05-01)

Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2025-05-01)

Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients
by: Pelagia I. Melea, et al.
Published: (2014-01-01)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
by: Carlyn Rose Tan, et al.
Published: (2025-04-01)

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
by: Salomon Manier, et al.
Published: (2025-03-01)

Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
by: Konstantinos Soureas, et al.
Published: (2025-03-01)

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm
by: Charlotte Pawlyn, et al.
Published: (2024-08-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
by: Sayalee V. Potdar, et al.
Published: (2025-05-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

T cell redirecting therapy for relapsed multiple myeloma
by: Melinda S. Y. Tan, et al.
Published: (2025-08-01)

Detection of early relapse in multiple myeloma patients
by: Tereza Růžičková, et al.
Published: (2025-01-01)

The Role of the Bone Marrow Microenvironment in Physical Function and Quality of Life in Patients with Multiple Myeloma After First-Line Treatment with Novel Agents and Autologous Transplantation
by: Polyxeni Spiliopoulou, et al.
Published: (2025-05-01)

Successful usage of external beam radiation to myeloma cutaneous lesions in patient with refractory, relapsed multiple myeloma
by: Chira Ranjan Khadanga, et al.
Published: (2019-01-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

Advances and perspective of the immunotherapy for relapsed/refractory multiple myeloma (interview)
by: S. V. Semochkin
Published: (2022-01-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
by: Evangelos Terpos, et al.
Published: (2025-02-01)

Hyperkyphotic changes in sagittal spinopelvic profile are associated with increased pain and impaired function in multiple myeloma patients
by: J. Kylies, et al.
Published: (2024-01-01)

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
by: Shah B, et al.
Published: (2025-04-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

MAMDC2‐AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma
by: Yifei Chen, et al.
Published: (2025-05-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review
by: Anna Svarna, et al.
Published: (2025-04-01)

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Oren Pasvolsky, et al.
Published: (2025-05-01)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
by: Efthymia Skafida, et al.
Published: (2023-01-01)

New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
by: OM Votyakova
Published: (2017-10-01)

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

A Rare Case of Extramedullary Relapse of Multiple Myeloma Causing Bowel Obstruction
by: Prarthna V. Bhardwaj, et al.
Published: (2019-01-01)

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter]
by: Gupta-Werner N, et al.
Published: (2025-07-01)

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis
by: Aaron S. Rosenberg, et al.
Published: (2025-08-01)

Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
by: Sijia Yan, et al.
Published: (2025-03-01)